Therapy-related acute myeloid leukemia secondary to histiocytic sarcoma

Minerva Med. 2021 Oct;112(5):655-657. doi: 10.23736/S0026-4806.19.06421-8. Epub 2020 Jan 20.

Authors

Wenying Wu¹, Yuchen Jing², Qian Xu³, Jia Hao³

Affiliations

¹ Interventional Operating Room, The First Hospital of China Medical University, Shenyang, China - yisheng_as@163.com.
² Department of Vascular Surgery, The First Hospital of China Medical University, Shenyang, China.
³ Interventional Operating Room, The First Hospital of China Medical University, Shenyang, China.

PMID: 31958922
DOI: 10.23736/S0026-4806.19.06421-8

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Cisplatin / therapeutic use
Cyclophosphamide / adverse effects
Doxorubicin / adverse effects
Doxorubicin / analogs & derivatives
Doxorubicin / therapeutic use
Etoposide / therapeutic use
Humans
Leukemia, Myeloid, Acute / chemically induced*
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Male
Neoplasms, Second Primary / chemically induced*
Polyethylene Glycols / therapeutic use
Prednisone / adverse effects
Sarcoma / drug therapy*
Sarcoma / pathology
Vincristine / adverse effects

Substances

Antineoplastic Agents
liposomal doxorubicin
Polyethylene Glycols
Vincristine
Etoposide
Doxorubicin
Cyclophosphamide
Cisplatin
Prednisone

Supplementary concepts

CHOP protocol